Journal of Breast Imaging最新文献

{"title":"Establishing an Evidence-based Modern Breast MRI Program.","authors":"Marco G Aru, Habib Rahbar, Debosmita Biswas, Suleeporn Y Sujichantararat, Brian Dontchos, Savannah C Partridge, Anum S Kazerouni","doi":"10.1093/jbi/wbaf082","DOIUrl":"10.1093/jbi/wbaf082","url":null,"abstract":"<p><p>Breast MRI has evolved over the past several decades into a cornerstone of breast imaging. Historically, dynamic contrast-enhanced (DCE) MRI has served as the foundation of breast MRI protocols for differentiation of benign and malignant lesions and was supplemented by additional sequences to refine diagnostic accuracy. More recently, advanced techniques, such as diffusion-weighted MRI, ultrafast DCE-MRI, and deep learning models, have further expanded capabilities of breast MRI. These innovations, however, have also contributed to substantial variability in breast MRI protocols across institutions. At the same time, the expanding indications for screening and diagnostic breast MRI are driving higher patient volumes, creating operational challenges for breast imaging centers tasked with balancing efficiency, accuracy, and limited resources. This review outlines the key elements and considerations of modern breast imaging protocols, discusses strategies for protocol optimization, and explores emerging technologies and future trends that are shaping the next generation of breast imaging.</p>","PeriodicalId":43134,"journal":{"name":"Journal of Breast Imaging","volume":" ","pages":"8-21"},"PeriodicalIF":2.0,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12900033/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146167011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ductal Carcinoma In Situ Active Monitoring Trials: Do Eligibility Criteria Identify Patients at Low Risk for Upgrade to Invasive Carcinoma?","authors":"Dana K Ataya, K Ruwani M Fernando, Jasmine Brainerd, Yarelis De La Cruz, Mahmoud Abdalah, Olya Stringfield, Elaheh Sobhani, Natarajan Raghunand, Marilyn Bui, Issam El Naqa, Bethany Lynn Niell","doi":"10.1093/jbi/wbaf085","DOIUrl":"https://doi.org/10.1093/jbi/wbaf085","url":null,"abstract":"<p><strong>Background: </strong>Ongoing active monitoring (AM) trials for women with ductal carcinoma in situ (DCIS) are investigating the safety and efficacy of monitoring DCIS lesions vs the current standard of care (surgical treatment). The frequency of upgrade in women undergoing AM for DCIS remains unknown.</p><p><strong>Objective: </strong>To evaluate the frequency of upgrade of DCIS at core-needle biopsy to invasive carcinoma at surgical excision among women who meet eligibility criteria for AM trials.</p><p><strong>Methods: </strong>A retrospective review between 2010 and 2023 was performed of women at an National Cancer Institute-designated comprehensive cancer center with a diagnosis of DCIS at core-needle biopsy who underwent subsequent surgical excision. Medical records were reviewed for clinical presentation, imaging findings, core biopsy, and final surgical pathology. Each patient was evaluated for AM trial eligibility based on published criteria for the LORD, LORIS, and COMET trials. Fisher's exact test compared proportions, with a P-value <.05 considered statistically significant.</p><p><strong>Results: </strong>Of 264 women, 10/264 (3.8%) were eligible for the LORD trial, 24/264 (9.1%) for the LORIS trial, and 64/264 (24.2%) for the COMET trial. Invasive carcinoma was found at surgical excision in 1/10 (10%) patients eligible for the LORD trial, 2/24 (8.3%) for the LORIS trial, and 9/64 (14.1%) for the COMET trial. All occult invasive carcinomas detected at surgical excision in trial-eligible patients were node-negative, with a median size of invasive cancer measuring 3.5 mm (interquartile range, 1-7 mm).</p><p><strong>Conclusion: </strong>A subset of women who meet eligibility criteria for DCIS AM trials are at risk for occult invasive carcinoma, with frequency of upgrade ranging from 8% to 14%.</p><p><strong>Clinical impact: </strong>More precise criteria and predictive biomarkers are needed to better stratify DCIS lesions and exclude women harboring invasive carcinomas from AM regimens.</p>","PeriodicalId":43134,"journal":{"name":"Journal of Breast Imaging","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147345388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Canadian Society Breast Imaging Position Statement on Mammographic Breast Density and Supplemental Screening.","authors":"Zina Kellow, Supriya Kulkarni, Paula B Gordon, Jean M Seely","doi":"10.1093/jbi/wbaf064","DOIUrl":"10.1093/jbi/wbaf064","url":null,"abstract":"<p><p>Screening aims to detect breast cancer before it becomes clinically apparent, enabling identification of tumors when they are smaller and have not yet spread and when treatment options are more effective, less invasive, and more affordable. However, screening mammography has known limitations, with breast density being a primary challenge. Denser breast tissue not only increases the likelihood of cancer but also makes tumors harder to detect due to overlapping tissue. Strong evidence now exists to support updating our previous guidelines to recommend supplemental screening beyond mammography for individuals with American College of Radiology category c or d breast density. Supplemental screening methods, such as MRI, contrast-enhanced mammography (CEM), or US (in that order of preference) can significantly improve cancer detection rates. We recognize that implementing these recommendations across Canada will present challenges. Nevertheless, a collaborative effort among radiologists, health care stakeholders, and policymakers is essential to drive gradual, meaningful improvements in breast cancer detection and outcomes.</p>","PeriodicalId":43134,"journal":{"name":"Journal of Breast Imaging","volume":" ","pages":"1-7"},"PeriodicalIF":2.0,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146158731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging Findings and Proposed Imaging Follow-up After Cryoablation for Treatment of Breast Cancer.","authors":"Heather V Garrett, Debbie L Bennett, Richard E Fine, Yolanda Bryce","doi":"10.1093/jbi/wbaf038","DOIUrl":"10.1093/jbi/wbaf038","url":null,"abstract":"<p><p>US-guided cryoablation has emerged as a promising minimally invasive treatment modality for breast cancer. With the growing adoption and success of cryoablation as a breast cancer treatment, many of these patients are undergoing routine follow-up imaging. There is a growing body of evidence and literature regarding the expected imaging appearance of the postcryoablation breast. Although there are limited data to provide guidelines for imaging and BI-RADS assessment after cryoablation, radiologists are seeking guidance in this area as they encounter these patients in their practice. Our objective is to provide an overview of the expected imaging findings after breast cryoablation and propose an imaging follow-up algorithm and BI-RADS assessment scheme in this patient population. Based on a review of the literature and the authors' clinical experience, we propose that patients should have initial imaging at 3 to 6 months after cryoablation. Subsequent surveillance imaging after cryoablation can be performed at 6- or 12-month intervals. Modalities of mammography with or without a contrast-enhanced study (MRI, contrast-enhanced mammography) should be used for follow-up imaging. BI-RADS assessment should be given on these imaging studies to aid in patient tracking and guide future interventions and imaging follow-up. For patients in whom cryoablation is considered a successful and definitive treatment and follow-up imaging shows expected postablation findings with no suspicious abnormalities, BI-RADS 2 assessment is appropriate. For patients in whom cryoablation was considered palliative and/or incomplete, BI-RADS 6 assessment can be given.</p>","PeriodicalId":43134,"journal":{"name":"Journal of Breast Imaging","volume":" ","pages":"87-95"},"PeriodicalIF":2.0,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146012806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contrast-Enhanced Mammography-Guided Biopsy for MRI-Detected Breast Lesions: A Prospective Study.","authors":"Yuying Cao, Amy H Lu, Ryan Cecil, Gordon S Abrams, Adrienne Vargo, Ruthane F Reginella, Bronwyn E Nair, Beatrice A Carlin, Dilip D Shinde, Marie A Ganott, Wendie A Berg, Jamie Y Hartman, Jules H Sumkin, Amy E Kelly, Denise M Chough, Margarita L Zuley","doi":"10.1093/jbi/wbaf044","DOIUrl":"10.1093/jbi/wbaf044","url":null,"abstract":"<p><strong>Objective: </strong>To determine the contrast-enhanced mammography-guided biopsy (CEM-Bx) success rate for MRI-suspicious lesions lacking known tomosynthetic or sonographic correlate along with factors associated with biopsy success.</p><p><strong>Methods: </strong>From June 2022 to August 2023, this prospective IRB-approved study enrolled women with breast MRI lesions rated BI-RADS ≥4A for CEM-Bx. Ipsilateral contrast-enhanced mammography (CEM) was performed in the biopsy suite and correlated with MRI. For visible lesions, CEM-Bx was performed immediately after prebiopsy CEM. Success criteria included enhancing correlate visualization and biopsy completion with accurate lesion sampling. An MRI-guided biopsy was recommended for failures. The success rate was evaluated with the Wilson score interval. MRI lesion and patient characteristics (size, type [mass, focus, or nonmass enhancement], kinetics, breast density, body mass index, background parenchymal enhancement [BPE], radiologist CEM experience, radiologist MRI experience, and histopathology) were collected. Multivariable logistic regression was performed with backward feature selection.</p><p><strong>Results: </strong>Analysis included 152 women (mean age 53 ± 11 years) with 184 lesions. CEM-Bx was successful for 106/184 (57.6%; [95% CI, 50.0-65.0]) lesions with 24/106 (22.6%) malignant. Of 78 failures, 60 (76.9%) lacked enhancement on prebiopsy CEM, 14 (17.9%) were not visualized with the biopsy grid, and 4 (5.1%) were not accurately sampled; 14/78 (17.9%) failures proved malignant. Increasing lesion size (odds ratio [OR] = 1.03; [95% CI, 1.01-1.06]), more years of radiologist CEM experience (OR = 1.24; [95% CI, 1.01-1.49]), and lower BPE (OR = 0.68 [95% CI, 0.46-0.98]) were associated with success.</p><p><strong>Conclusion: </strong>Contrast-enhanced mammography biopsy can be a successful alternative to MRI-guided biopsy for MRI-detected lesions. MRI-guided biopsy should be pursued if CEM-Bx fails.</p>","PeriodicalId":43134,"journal":{"name":"Journal of Breast Imaging","volume":" ","pages":"42-54"},"PeriodicalIF":2.0,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146143794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Follow-up Recommendations for Young, Average Risk Women With BI-RADS 3 Masses.","authors":"Katie Shpanskaya, Derek L Nguyen, Lars J Grimm, Sujata V Ghate","doi":"10.1093/jbi/wbaf042","DOIUrl":"10.1093/jbi/wbaf042","url":null,"abstract":"<p><strong>Objective: </strong>To determine the outcome and malignancy rate of BI-RADS 3 masses during follow-up at 6, 12, and 24 months.</p><p><strong>Methods: </strong>This retrospective cohort study identified female patients <35 years of age with an oval, parallel, circumscribed mass assigned a BI-RADS 3 assessment on US from January 2014 to December 2021. Inclusion criteria were average risk women with a 6-month follow-up US and either (1) ≥18 months of follow-up imaging or (2) surgical excision/biopsy. Initial US lesion characteristics; follow-up BI-RADS assessments at 6, 12, 18, and 24 months; and pathology results were recorded.</p><p><strong>Results: </strong>There were 662 patients with a BI-RADS 3 mass on US, of whom 191 were patients (mean age 26.4 ± 6.0 years) with 228 lesions (mean size 1.6 ± 0.7 cm) who met inclusion criteria. Most lesions exhibited either 2-year stability (56%, 128/228) or decreased in size/resolved (8%, 18/228). In all, 31% (71/228) of lesions were biopsied, most commonly because of increasing size (93%, 66/71). Most enlarging lesions underwent biopsy at the 6-month follow-up (68%, 45/66). All 71 lesions recommended for biopsy were fibroadenomas with a positive predictive value and malignancy rate of 0%. No phyllodes tumors were detected.</p><p><strong>Conclusion: </strong>There were no cancers among young female patients with probably benign (BI-RADS 3) masses on US. A single 6-month imaging follow-up and then ongoing clinical surveillance may be sufficient in assessing probably benign masses in young women aged <35 years.</p>","PeriodicalId":43134,"journal":{"name":"Journal of Breast Imaging","volume":" ","pages":"22-31"},"PeriodicalIF":2.0,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13017415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145490460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Acute and Delayed Contrast Reactions With Multiple Exposures to Contrast-Enhanced Mammography-Experience From the TOCEM Trial.","authors":"Lin Gu, Ufara Zuwasti, McKenna Rigling, Wendie A Berg","doi":"10.1093/jbi/wbaf043","DOIUrl":"10.1093/jbi/wbaf043","url":null,"abstract":"<p><strong>Objective: </strong>To detail acute and delayed contrast reactions associated with contrast-enhanced mammography (CEM) in a prospective screening trial.</p><p><strong>Methods: </strong>In an institutional review board-approved protocol from October 2019 through July 2024, women with personal history of breast cancer received up to 3 rounds of annual supplemental screening CEM. Intravenous iopamidol (370 mg/mL) was administered via automated injector. Adverse events within 1 week of contrast administration were recorded.</p><p><strong>Results: </strong>A total of 1651 women (mean age at entry: 63.2 years) received 3873 contrast injections (1651, 1326, and 896 in years 1, 2, and 3, respectively). Among 3873 injections, we observed 38 (0.98%) contrast reactions in 35 unique participants, including 25/3873 (0.65%) allergic-like reactions (15/1651 [0.91%] in year 1, 7/1326 [0.53%] in year 2, and 3/896 [0.33%] in year 3), 9/3873 (0.23%) physiologic reactions, and 4/3873 (0.10%) other reactions. Of 25 allergic-like reactions, 20 (80%) were cutaneous (hives/rash). One participant had bronchospasm, 1 had scratchy throat, 1 had shortness of breath, 1 sneezed repeatedly, and 1 had watery eyes. Five allergic-like reactions were delayed, including hives in 4 (2 at 1 day, 1 at 2-3 days, and one 7 days later) and watery eyes in 1; 2 physiologic reactions were delayed. Two of 25 reactions were immediate, and imaging was not completed; medication was given to 15/25 (60%). Allergic-like reactions occurred in 14/3328 (0.42%) examinations in women with prior uneventful iodinated contrast exposure, 10/510 (1.96%) among those naïve to contrast (P <.001), and 1 woman with recurrent but initially unreported reaction in year 1. No allergic-like reactions were observed in 34 examinations (19 women) premedicated for prior allergic contrast reaction.</p><p><strong>Conclusion: </strong>We observed a low rate and usually mild severity of adverse reactions to iodinated contrast in CEM with trained staff.</p>","PeriodicalId":43134,"journal":{"name":"Journal of Breast Imaging","volume":" ","pages":"55-65"},"PeriodicalIF":2.0,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146143852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Axillary US: How Indication and Breast Cancer Status Impact Diagnostic Outcomes.","authors":"Howard Z Yan, Tie Liang, Wendy B DeMartini, Sarah M Pittman, Brittany Z Dashevsky, Eric L Rosen, Debra M Ikeda, Uzma Waheed, Jafi A Lipson, Steven P Poplack","doi":"10.1093/jbi/wbaf040","DOIUrl":"10.1093/jbi/wbaf040","url":null,"abstract":"<p><strong>Objective: </strong>To determine how indication and breast cancer status impact the observed prevalence of lymph node (LN) metastases, axillary US (AxUS) performance indices, and sonographic presentation of metastatic LNs.</p><p><strong>Methods: </strong>In total, 2156 consecutive AxUS examinations in 1719 women >18 years old from May 22, 2017, to December 10, 2020, were identified. Indication, breast cancer status, and imaging results were obtained. Lymph node status was established ≥1 year follow-up. Axillary US examinations were reviewed, blinded to clinical and pathology outcomes. Axillary US performance indices were compared by cancer status using an unpaired proportion test. Lymph node characteristics between breast cancer statuses were assessed using logistic regression analysis.</p><p><strong>Results: </strong>Observed LN metastases prevalence in the overall study population was 1.7% (23/1340). In all, 62.2% (1340/2156) of AxUS examinations were performed in women without breast cancer; \"Treatment planning\" made up only 5% (108/2156) and had the highest prevalence-24.1% (26/108). Lymph node metastases prevalence was between 0% and 0.7% for all indications in women without breast cancer other than AxUS prompted by another imaging modality. \"Follow-up\" and \"routine\" axillary evaluation during diagnostic breast US had a combined prevalence of 0.20% (1/504). Metastatic LNs in women without current/suspected breast cancer had larger cortices and were more likely to have an absent hilum and abnormal shape.</p><p><strong>Conclusion: </strong>This study highlights the need to incorporate examination indication and cancer status during AxUS interpretation, particularly in women without current or suspected breast cancer. It is also important to be cognizant of observed differences in sonographic features of LN metastasis based on breast cancer status.</p>","PeriodicalId":43134,"journal":{"name":"Journal of Breast Imaging","volume":" ","pages":"66-76"},"PeriodicalIF":2.0,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146158741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SCOUT Localization at Time of Lymph Node Biopsy.","authors":"Meng Hao, Steven P Poplack, Jean Bao, Jacqueline Tsai, Tie Liang, Jason Wong, Brittany Z Dashevsky","doi":"10.1093/jbi/wbaf049","DOIUrl":"10.1093/jbi/wbaf049","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the utility of SCOUT radar localization (SCOUT) placement at the time of axillary lymph node (LN) biopsy.</p><p><strong>Methods: </strong>A retrospective study was conducted on SCOUT placement during axillary LN core-needle biopsy (CNB) between January 2018 and September 2023. The SCOUT was considered utilized if detected and removed during targeted axillary dissection with or without subsequent axillary LN dissection. Analysis was performed with a Fisher's exact test and Wilcoxon rank-sum test to determine association of features with either LN disease status or SCOUT utilization.</p><p><strong>Results: </strong>SCOUT placement was performed in 127 patients during US-guided CNB, with 77% (98/127) malignant and 23% (29/127) benign results. Three patients were lost to follow-up and excluded. SCOUTs placed during LN biopsy were utilized in 70% (87/124) of patients. A total of 104 patients underwent axillary surgery, including 80 malignant and 24 benign CNB specimen cases. The SCOUT-localized node did not take up blue dye or radiotracer in 28% (22/80) of patients with malignant CNB LNs, 86% (19/22) of whom were in postneoadjuvant treatment. SCOUTs were not utilized for 30% (37/124) of patients. Age was a significant predictor of SCOUT utilization, with 87% (40/46) of utilization among patients <50 years old (P <.001). Among the 24 patients with benign CNB specimens who underwent axillary surgery, 25% (6/24) had nodal metastasis, of which 50% (3/6) were within the SCOUT-localized node.</p><p><strong>Conclusion: </strong>SCOUTs placed at the time of LN biopsy facilitate detection of the biopsied node and may be particularly beneficial after neoadjuvant treatment and in women <50 years old.</p>","PeriodicalId":43134,"journal":{"name":"Journal of Breast Imaging","volume":" ","pages":"32-41"},"PeriodicalIF":2.0,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146158747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postcryoablation Breast Imaging Algorithms, Findings, and Standardized Reporting.","authors":"Monica L Huang, Deanna L Lane, Lauren Q Chang Sen, Rosalind P Candelaria, Lumarie Santiago","doi":"10.1093/jbi/wbaf050","DOIUrl":"10.1093/jbi/wbaf050","url":null,"abstract":"<p><p>Breast cryoablation for the treatment of fibroadenoma and breast cancer is safe and effective, and breast cryoablation performed as an outpatient procedure with local anesthesia alone is well tolerated by patients. Because use of this procedure is increasing, radiologists and proceduralists must understand the postcryoablation breast imaging algorithms, including the rationale for imaging, the appropriate timing for imaging, and appropriate imaging modalities. Radiologists must also be able to differentiate benign, expected posttreatment findings at the ablation zone from findings suggestive of residual, progressing, or recurrent malignancy on mammography, digital breast tomosynthesis, US, MRI, and contrast-enhanced mammography. Finally, radiologists must report postcryoablation breast imaging findings using appropriate descriptors and standardized reporting lexicon. Accurate and standardized reporting of postcryoablation breast imaging findings is important to guide clinical management, facilitate research on imaging findings' associated risk for malignancy, and permit comparison of radiologist performance and patient outcomes across facilities worldwide.</p>","PeriodicalId":43134,"journal":{"name":"Journal of Breast Imaging","volume":" ","pages":"96-108"},"PeriodicalIF":2.0,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146012724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}